Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PHARM.AS
- Price
- 0.71
- Stock movement down
- -0.01 (-1.19%)
- Company name
- Pharming Group NV
- Exchange
- (AS ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 480.27M
- Ent value
- 619.33M
- Price/Sales
- 1.68
- Price/Book
- 2.13
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -29.06%
- 3 year return
- -4.09%
- 5 year return
- -12.17%
- 10 year return
- 8.18%
Last updated: 2025-04-05
DIVIDENDS
PHARM.AS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 1064.91 |
| Price to FCF | - |
| Price to EBITDA | 51.27 |
| EV to EBITDA | 66.12 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.68 |
| Price to Book | 2.13 |
| EV to Sales | 2.17 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 678.35M |
| EPS (TTM) | -0.03 |
| FCF per share (TTM) | -0.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 285.75M |
| Gross profit (TTM) | 255.44M |
| Operating income (TTM) | -14.26M |
| Net income (TTM) | -17.82M |
| EPS (TTM) | -0.03 |
| EPS (1y forward) | -0.01 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.39% |
| Operating margin (TTM) | -4.99% |
| Profit margin (TTM) | -6.24% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 60.66M |
| Net receivables | 48.20M |
| Total current assets | 282.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 30.67M |
| Total assets | 425.51M |
| Accounts payable | 72.64M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 79.84M |
| Total liabilities | 199.72M |
| Shareholder's equity | 225.79M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 451.00K |
| Capital expenditures (TTM) | 991.00K |
| Free cash flow (TTM) | -540.00K |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -7.89% |
| Return on Assets | -4.19% |
| Return on Invested Capital | -5.61% |
| Cash Return on Invested Capital | -0.17% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.71 |
| Daily high | 0.73 |
| Daily low | 0.70 |
| Daily Volume | 8.57M |
| All-time high | 306.70 |
| 1y analyst estimate | 1.70 |
| Beta | 0.81 |
| EPS (TTM) | -0.03 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PHARM.AS | S&P500 | |
| Current price drop from All-time high | -99.77% | -17.56% |
| Highest price drop | -99.98% | -56.47% |
| Date of highest drop | 23 Apr 2013 | 9 Mar 2009 |
| Avg drop from high | -93.21% | -11.07% |
| Avg time to new high | 287 days | 12 days |
| Max time to new high | 6404 days | 1805 days |
COMPANY DETAILS
Marketcap
480.27M
Marketcap category
Small-cap
Description
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Employees
382
Website
Investor relations
-
SEC filings
CEO
Country
Netherlands
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended Decemb...
April 3, 2025
Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor confe...
March 28, 2025
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate cl...
March 20, 2025
Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.
March 14, 2025
The European market has recently experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending lower amid ongoing uncertainty about U.S. trade policy. Despite these challenges, th...
March 14, 2025
Pharming Group ( AMS:PHARM ) Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023). Net...
March 14, 2025
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenu...
March 13, 2025
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholder...
March 4, 2025
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor co...
February 28, 2025
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2...
February 27, 2025
Next page